Showing posts with label Deaths. Show all posts
Showing posts with label Deaths. Show all posts

Tuesday, 29 October 2013

Childhood Gun Injuries, Deaths on Rise in U.S., Study Finds

News Picture: Childhood Gun Injuries, Deaths on Rise in U.S., Study Finds

MONDAY, Oct. 28 (HealthDay News) -- Gunshot wounds put about 7,500 children in the hospital and cause 500 in-hospital child deaths each year in the United States, according to a new study.

And these pediatric shooting injuries and fatalities are increasing, the researchers said.

The analysis of national data also found a significant association between the percentage of gunshot wounds that occur in homes and the percentage of homes with guns, according to the study, which was presented Sunday at the national conference of the American Academy of Pediatrics in Orlando, Fla.

"Handguns account for the majority of childhood gunshot wounds, and this number appears to be increasing over the last decade," study lead author Dr. Arin Madenci said in an academy news release. "Furthermore, states with higher percentages of household firearm ownership also tended to have higher proportions of childhood gunshot wounds, especially those occurring in the home."

Child hospitalizations for gunshot wounds increased from about 4,300 in 1997 to more than 7,700 in 2009, the study found. In-hospital child deaths from gunshot wounds rose from 317 to 503 during that time.

Many current gun-control efforts focus on limiting the availability of military-style semi-automatic assault rifles. "[However], policies designed to reduce the number of household firearms, especially handguns, may more effectively reduce the number of gunshot injuries in children," Madenci said.

Another study presented at the meeting examined the types of injuries among more than 450 gunshot victims younger than age 18 who were treated at an urban trauma center between 2005 and 2010. Of those patients, 78 were younger than 14 years old, 86 percent were male and 80 percent were black. The death rate was 7 percent.

Patients aged 5 to 9 years old were six times more likely than those aged 10 to 14 to have multiple injury sites.

Study author Dr. Phyllis Hendry said further analysis of firearm injury data found that children younger than 14 differ from older teens in several key areas.

"They are four times more likely to be shot at home and are much more likely to arrive by ambulance than by private car or walk-in," Hendry said in the news release, noting that older teens often walk in or get dropped off at emergency-room entrances. "Over 60 percent of the time, the shooter and the type of firearm were unknown."

The researchers said emergency records often lack important details that are needed to help develop effective crime and injury-prevention strategies. They recommend improving the links between emergency medical services, hospital and law-enforcement records.

-- Robert Preidt MedicalNews
Copyright © 2013 HealthDay. All rights reserved. SOURCE: American Academy of Pediatrics, news release, Oct. 28, 2013



View the original article here

Tuesday, 25 June 2013

FDA Probes Deaths Linked to Long-Acting Zyprexa

Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up
By John Gever, Deputy Managing Editor, MedPage Today

SILVER SPRING, Md. -- Two patients died 3-4 days after injections with the long-acting antipsychotic drug olanzapine pamoate (Zyprexa Relprevv), prompting an FDA investigation.

The agency has not determined whether the drug caused the fatalities. "At this time, FDA is continuing to evaluate these deaths and will provide an update when more information is available," it said in a statement Tuesday.

Both patients received intramuscular injections of the drug at appropriate doses, the FDA said, but tests showed "very high olanzapine blood levels after death."

High doses are known to induce delirium, cardiopulmonary arrest, cardiac arrhythmias, and impaired consciousness ranging from sedation to coma.

The long-acting form of olanzapine was approved with a risk evaluation and mitigation strategy that requires patients to remain in the clinic for a 3-hour monitoring period and to be escorted home afterward. The requirement was imposed after some patients in clinical trials became delirious or lost consciousness shortly after receiving injections.

These events, dubbed post-injection delirium-sedation syndrome (PDSS), were traced to an unexpectedly rapid release of olanzapine into circulation leading to very high blood levels of the drug.

However, all those cases occurred within hours of injection, not days, and no deaths were attributed to the syndrome, the FDA said.

Olanzapine pamoate is approved for injection every 2-4 weeks for treating patients with schizophrenia. It is one of several long-acting formulations of "atypical" antipsychotic drugs currently available. PDSS has not been seen with those other products.

John Gever

Senior Editor

John Gever, Senior Editor, has covered biomedicine and medical technology for 30 years. He holds a B.S. from the University of Michigan and an M.S. from Boston University. Now based in Pittsburgh, he is the daily assignment editor for MedPage Today as well as general factotum on the reporting side. Go Pirates/Penguins/Steelers!